Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
EDMONTON - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) announced Tuesday the introduction of its Whistler Cannabis Co. brand to the Australian medical cannabis market with two high-potency products. The company’s expansion comes amid strong recent performance, with shares gaining over 13% in the past week, according to InvestingPro data.
The Canadian medical cannabis company is launching two cultivars in Australia: Ginger Breath with 32% THC and Critical Diesel with 28% THC. Both products will be available in 10-gram packages. This international expansion builds on Aurora’s robust revenue growth of 28.6% over the last twelve months, with the company maintaining a healthy liquidity position as evidenced by a current ratio of 2.97.
"Whistler is a tried-and-true brand in the Canadian market," said Andre Jerome, Executive Vice President of Global Business Development at Aurora, according to the company’s press release. "We’re excited to now extend its legacy, and our Canadian cultivation expertise, to Australian patients."
First developed in 2013, Whistler Cannabis products are cultivated at Aurora’s facility in Pemberton Valley, British Columbia. The company states the cannabis is produced in small batches using proprietary genetics, then hang-dried and hand-trimmed.
The Ginger Breath cultivar, bred from ’91 Royale and Driftwood Diesel genetics, features a terpene profile of Caryophyllene, Pinene, and Linalool. Critical Diesel, derived from Critical Sensi Star and Driftwood Diesel lineages, contains Caryophyllene, Pinene, and Myrcene terpenes.
Aurora Cannabis, headquartered in Edmonton, Alberta, operates in multiple international markets including Canada, Europe, Australia, and New Zealand. The company’s product portfolio spans both medical and consumer cannabis brands.
The company’s common shares trade on the NASDAQ and Toronto Stock Exchange under the symbol "ACB."
In other recent news, Aurora Cannabis reported its first-quarter 2025 earnings, significantly surpassing revenue expectations. The company achieved a net revenue of $98 million, exceeding the forecasted $70.33 million by 39.37%. This development marks a notable achievement for Aurora Cannabis in its financial performance. In addition to the earnings news, major cannabis companies, including Aurora Cannabis, experienced stock surges following reports that President Donald Trump is considering reclassifying marijuana as a less dangerous drug. This potential regulatory change could transform the cannabis industry’s landscape. Canopy Growth Corp’s stock surged by 19.2%, while Aurora Cannabis saw an 8.7% increase. Other companies like Tilray and Cronos Group also experienced significant gains. These recent developments reflect a dynamic period for the cannabis industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.